HLB Elevar expands contacts with global medical professionals at ESMO 2026
Predicted impact: Low
Conference presence and chairman's routine share buying; small effect.
HLBHLB
028300 · KOSDAQ · ₩028300 · HLB
₩40,650▲ ₩750 (1.88%)End-of-day · Oct 28, 2026 · End-of-day prices.
HLB prepares US launch of bile duct cancer drug after liver cancer drug, presenting clinical results at ESMO
Predicted impact: Low
Drug launch preparation and conference data; no revenue size or approval event given.
HLB Elevar attends European Society for Medical Oncology congress, engaging with global medical professionals
Predicted impact: Low
HLB Life & Health's 'Tetrapos' Enters E-Mart WOOW Shop, Expanding Offline Footprint
Predicted impact: Low
Routine retail shelf placement with no disclosed size.
HLB Life & Health expands offline distribution channels for 'Tetrapos'
Predicted impact: Low
Expanded offline distribution for a consumer product; small commercial change.
HLB Chairman Jin Yang-gon buys additional 80,000 affiliate shares
Predicted impact: Low
Additional 80,000 affiliate share purchases; follows the earlier insider buying pattern, small size.
HLB Group Chairman Jin Yang-gon buys affiliate shares 15 times in a month through personal company
Predicted impact: Medium
Group chairman buying affiliate shares 15 times in a month; insider buying signal, modest size.
[BioS] HLB Verismo: preclinical results of solid tumor CAR-T to be presented at SITC
Predicted impact: Low· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
Preclinical CAR-T data to be presented at a conference; early-stage with no financial size.
After Five Failed Clinical Trials, Will HLB's Eye Drug Turn Things Around with Its November US Phase 3 Results?
Predicted impact: Medium· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
US Phase 3 eye drug result due in November; company revenue is small versus its value.
[BioS] HLB, After FDA Approval of 'Rifitu,' Announces Group Mid-to-Long-Term Strategy
High impactPredicted impact: High· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
FDA approval of Rifitu drug, a major regulatory ruling; large for a ₩5.4T company.
Knock-on:HLB Life ScienceMoves with HLB (corr 0.90); moved with HLB on 17 of its 18 biggest daysHLB PharmaceuticalMoves with HLB (corr 0.87); moved with HLB on 15 of its 16 biggest days
HLB Group Chairman Kim Tae-han says liver cancer drug approval could come as early as this year
Predicted impact: Medium· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
Chairman expects FDA approval this year on liver cancer drug; a key catalyst but repeated statements in last 14 days.
HLB Chairman Kim Tae-han says issues with rivoceranib production facility resolved, confident of FDA approval
Predicted impact: Low· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
Management reiterates FDA approval confidence; the same expectation was already stated this period.
HLB unveils pipelines of five companies in Yeouido, aims to join global top 100 by 2030
Predicted impact: Low· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
Pipeline showcase and 2030 goal; largely repeats recent HLB pipeline commentary.
HLB Chairman Jin Yang-gon: 'Open to cooperation with Big Pharma on Repitu's US market'
Predicted impact: Medium· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
Liver cancer drug FDA approval hopes and US partnering openness already discussed repeatedly over recent days.
HLB co-heads Jin Yang-gon and Kim Tae-han confident on liver cancer drug FDA approval: "Expect approval within this year"
Predicted impact: Low· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
Co-heads' confidence on approval within the year repeats recent statements; no new decision.
"This time you can really look forward to it"... Why HLB is confident about its fourth attempt with liver cancer drug
Predicted impact: Low· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
Management confidence on the liver cancer drug repeats prior pipeline commentary; no new event.
HLB re-files for FDA approval of liver cancer combination therapy; expects decision within the year after resolving manufacturing issues
Predicted impact: Low· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
FDA re-filing and expected decision timing were already reported in recent days; expectation only, no ruling yet.
HLB: full-scale US commercialization of bile duct cancer drug under way…liver cancer drug approval also accelerating
Predicted impact: Low· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
US commercialization and guideline inclusion were already reported; medium lowered to low.
Im Chang-yun, HLB Vice Chairman: 'Revaluation of affiliates' pipelines will prove corporate value through results'
Predicted impact: Low· Actual: −8.0% vs sector, volume 0.4× normal (5 trading days)
Vice chairman's general comments on affiliate pipelines; no new financial figures given.
HLB Group: Chairman Jin Yang-gon buys shares in HLB Zenith
Predicted impact: Low· Actual: −1.7% vs sector, volume 1.0× normal (5 trading days)
Chairman's routine affiliate share purchases; repeated pattern of buying already reported.
Also known as: HLB / 028300 / KRX:028300
Source: KRX statistical information